2025年度业绩快报公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 本公告所载北京佰仁医疗科技股份有限公司（以下简称"公司"）2025年度主要财务数据为初步核算数 据，未经会计师事务所审计，具体数据以公司2025年年度报告中披露的数据为准，提请投资者注意投资 风险。 一、2025年度主要财务数据和指标 证券代码：688198 证券简称：佰仁医疗 公告编号：2026-001 北京佰仁医疗科技股份有限公司 单位：人民币万元 ■ 公司于2020年7月实施第二类限制性股票激励计划并首次授予了限制性股票，为便于投资者了解公司实 际经营的财务状况，将剔除股份支付影响的财务数据及指标列示如下： 单位：人民币万元 ■ 注：1、本报告期初数同法定披露的上年年末数。 2、以上财务数据及指标以合并报表数据填制，但未经审计，最终数据以公司2025年年度报告中披露的 数据为准。 3、以上数据及指标若有尾差，为四舍五入所致。 二、经营业绩和财务状况情况说明 1、报告期内，公司充分发挥植入材料和器械创新平台的优势，多产品线在应对行业政策或竞争环境 ...

Core Viewpoint - The approval of the ePTFE membrane product by the National Medical Products Administration marks a significant development for Baijun Medical, as it ends the reliance on imported ePTFE membranes in the domestic market [1] Company Summary - Baijun Medical (688198) announced the approval of its ePTFE membrane product for registration, which is a 0.1mm expanded polytetrafluoroethylene membrane [1] - The product is intended for the repair or reconstruction of the pericardium in cardiac surgery [1] Industry Summary - The current market for pericardial membranes in China has been dominated by foreign companies, leading to a long-standing dependence on imports [1] - The registration and upcoming market entry of Baijun Medical's product will disrupt this import reliance, potentially transforming the domestic market landscape for cardiac surgical materials [1]

Group 1 - The core point of the article is that Baijun Medical (688198.SH) has received approval from the National Medical Products Administration for its ePTFE product, which is used for the repair or reconstruction of the pericardium during cardiac surgeries [1] - The ePTFE membrane is 0.1mm thick and serves to protect the heart surface, particularly the coronary vessels, during surgical procedures [1] - The approval of this product will end the reliance on imported ePTFE pericardial membranes in the domestic market, which has been dominated by foreign companies for a long time [1] Group 2 - The pericardium is a thin membrane that envelops the heart, and surgical damage to it can lead to serious complications, especially in pediatric patients with complex congenital heart disease [1] - The need for ePTFE membranes in cardiac surgeries is critical, as they are routinely used to repair or reconstruct damaged pericardium to protect the heart [1] - The introduction of this product is expected to significantly impact the market by providing a domestic alternative to previously imported solutions [1]